stella
beta
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation — Stella
Recruiting
Back to EGFR trials
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations
(2 sites)
China
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality
Shandong Tumor Hospital, Shandong, Jinan
View full record on ClinicalTrials.gov